MedPath

Study of Chicory per oral administration effect in decreasing serum Ferritin level in major and intermediate beta thalassemia patient.

Not Applicable
Conditions
Major Thalassemia.
Beta thalassaemia
Registration Number
IRCT2016112514333N61
Lead Sponsor
Vice chancellor for research, Kermanshah University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
100
Inclusion Criteria

Patients with thalassemia major; Patients with serum ferritin between 1000 and 3000.
Exclusion criteria: Patients with heart failure, hypertension and diabetes; Patients who have more than 3,000 ferritin in routine check

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum ferritin levels. Timepoint: Baseline, two months after the start of treatment and two months after the end of treatment. Method of measurement: Based on lab.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath